• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PACS Group Announces Appointment of Evelyn Dilsaver to Serve as Independent Board Director

    5/13/24 7:31:00 PM ET
    $HQY
    $QDEL
    $TPX
    Real Estate
    Real Estate
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HQY alert in real time by email

    PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward."

    "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver.

    Ms. Dilsaver also serves on the boards of directors of Tempur Sealy International (NYSE:TPX), HealthEquity, Inc. (NASDAQ:HQY) and QuidelOrtho (NASDAQ:QDEL). Ms. Dilsaver was President and Chief Executive Officer of Charles Schwab Investment Management from July 2004 until September 2007. Prior to that, she held various senior management positions with The Charles Schwab Corporation. Ms. Dilsaver is a certified public accountant and holds a B.S. degree in accounting from California State University-Hayward.

    Ms. Dilsaver is an independent director under applicable NYSE and SEC rules. Her appointment now makes the PACS Board of Directors majority independent. Ms. Dilsaver's committee appointments will be considered at a later date.

    About PACS Group

    PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 20,000 patients daily.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240513694766/en/

    Get the next $HQY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HQY
    $QDEL
    $TPX

    CompanyDatePrice TargetRatingAnalyst
    QuidelOrtho Corporation
    $QDEL
    10/7/2025$33.00Buy → Neutral
    Citigroup
    HealthEquity Inc.
    $HQY
    5/22/2025$105.00 → $112.00Outperform
    RBC Capital Mkts
    QuidelOrtho Corporation
    $QDEL
    5/8/2025$44.00Hold → Buy
    Jefferies
    HealthEquity Inc.
    $HQY
    3/25/2025$120.00 → $115.00Outperform → Strong Buy
    Raymond James
    Tempur Sealy International Inc.
    $TPX
    2/5/2025Mkt Perform → Outperform
    William Blair
    Tempur Sealy International Inc.
    $TPX
    2/3/2025$67.00 → $80.00Neutral → Outperform
    Wedbush
    QuidelOrtho Corporation
    $QDEL
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    QuidelOrtho Corporation
    $QDEL
    12/10/2024$43.00Hold
    Jefferies
    More analyst ratings

    $HQY
    $QDEL
    $TPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QuidelOrtho to Report Third Quarter 2025 Financial Results

    SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relat

    10/22/25 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025

    FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion medicine SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, will highlight its ongoing commitment to transfusion medicine excellence at the Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting. The company's participation coincides with the recent FDA approval of its Micro Typing Systems (MTS) DAT Card and the continued expansion of its comprehensive direct antiglobulin testing and immunohematology portfolio.

    10/16/25 8:30:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Introduces GLP-1 Telehealth and Direct HSA Enrollment Platforms

    DRAPER, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY), the nation's largest Health Savings Accounts (HSAs) and consumer-directed benefits administrator, today announced two consumer-focused initiatives designed to expand access to affordable healthcare solutions for millions of American families: a curated platform connecting HealthEquity HSA members with affordable healthcare solutions beginning with GLP-1 weight management medications, and a direct HSA enrollment platform. The new offerings coincide with National HSA Awareness Day and the start of open enrollment season. HSAs are experiencing unprecedented growth as Americans seek solutions to rising healthcare

    10/14/25 8:00:00 AM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    QuidelOrtho downgraded by Citigroup with a new price target

    Citigroup downgraded QuidelOrtho from Buy to Neutral and set a new price target of $33.00

    10/7/25 8:58:45 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    RBC Capital Mkts resumed coverage on HealthEquity with a new price target

    RBC Capital Mkts resumed coverage of HealthEquity with a rating of Outperform and set a new price target of $112.00 from $105.00 previously

    5/22/25 9:53:52 AM ET
    $HQY
    Real Estate

    QuidelOrtho upgraded by Jefferies with a new price target

    Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

    5/8/25 9:44:58 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP of R&D & CTO Siegrist Jonathan Philip was granted 18,656 shares and covered exercise/tax liability with 6,676 shares (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    10/17/25 4:16:37 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Legal Officer Hodges Michelle A was granted 390 shares and covered exercise/tax liability with 199 shares, increasing direct ownership by 0.65% to 29,403 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    10/17/25 4:14:34 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    EVP, General Counsel Ladd Delano covered exercise/tax liability with 977 shares, decreasing direct ownership by 1% to 78,479 units (SEC Form 4)

    4 - HEALTHEQUITY, INC. (0001428336) (Issuer)

    10/8/25 8:59:42 PM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    12/13/24 4:12:57 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/26/24 6:48:23 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    SEC Filings

    View All

    SEC Form 144 filed by HealthEquity Inc.

    144 - HEALTHEQUITY, INC. (0001428336) (Subject)

    10/8/25 4:15:51 PM ET
    $HQY
    Real Estate

    SEC Form 144 filed by HealthEquity Inc.

    144 - HEALTHEQUITY, INC. (0001428336) (Subject)

    9/5/25 4:08:20 PM ET
    $HQY
    Real Estate

    SEC Form 10-Q filed by HealthEquity Inc.

    10-Q - HEALTHEQUITY, INC. (0001428336) (Filer)

    9/2/25 4:03:47 PM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Leadership Updates

    Live Leadership Updates

    View All

    HealthEquity Strengthens Executive Leadership Team with Strategic Appointments to Drive Growth and Innovation

    DRAPER, Utah, Sept. 25, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY), the nation's largest Health Savings Accounts (HSAs) and consumer-directed benefits administrator, today announced the appointment of new senior executives to accelerate the company's strategic vision and capitalize on expanding market opportunities. Mukund Ramachandran joins as Chief Marketing Officer and Garett Kitch as Senior Vice President of Client Sales & Relationship Management, effective September 29, 2025. The appointments come as HealthEquity continues to execute against record financial performance, alongside the largest HSA eligibility expansion in 20 years following recent federal legislation.

    9/25/25 9:00:00 AM ET
    $HQY
    Real Estate

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Reports Year-End Sales Metrics

    DRAPER, Utah, Feb. 18, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced its HSAs, HSA Assets and Total Accounts as of its fiscal year ended January 31, 2025. The Company also affirmed its guidance for fiscal 2025 and 2026, provided an updated HSA cash repricing schedule, and announced upcoming events and presentations. The total number of HSAs as of January 31, 2025 was 9.9 million, an increase of 14%, from 8.7 million as of January 31, 2024. The Company closed its fiscal year 2025 with 17.0 million Total Accounts, an increase of 9%, from 15.7 million as of January 31,

    2/18/25 4:01:00 PM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Financials

    Live finance-specific insights

    View All

    QuidelOrtho to Report Third Quarter 2025 Financial Results

    SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relat

    10/22/25 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Reports Second Quarter Ended July 31, 2025 Financial Results

    Highlights of the second quarter include: Revenue of $325.8 million, an increase of 9% compared to $299.9 million in Q2 FY25.Net income of $59.9 million, an increase of 67% compared to $35.8 million in Q2 FY25, with non-GAAP net income of $94.6 million, an increase of 24% compared to $76.3 million in Q2 FY25.Net income per diluted share of $0.68, an increase of 70% compared to $0.40 in Q2 FY25, with non-GAAP net income per diluted share of $1.08, an increase of 26% compared to $0.86 in Q2 FY25.Adjusted EBITDA of $151.1 million, an increase of 18% compared to $128.3 million in Q2 FY25.10.0 million HSAs, an increase of 6% compared to Q2 FY25.Total HSA Assets of $33.1 billion, an increase of

    9/2/25 4:01:00 PM ET
    $HQY
    Real Estate

    HealthEquity Announces Dates to Report Second Quarter Earnings and Presentations at Investor Conferences

    DRAPER, Utah, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced plans to release its second quarter of fiscal 2026 financial results following the close of regular stock market trading hours on Tuesday, September 2, 2025. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, September 2, 2025, at 4:30 p.m. Eastern Time during which management will review the Company's financial results. HealthEquity Second Quarter Fiscal Year 2026 Results Conference CallDate: September 2, 2025Time: 4:30 p.m. Eastern Time /

    8/6/25 9:00:00 AM ET
    $HQY
    Real Estate